{"nctId":"NCT00882713","briefTitle":"A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia","startDateStruct":{"date":"2009-02"},"conditions":["Anemia"],"count":202,"armGroups":[{"label":"C.E.R.A.","type":"EXPERIMENTAL","interventionNames":["Drug: methoxy polyethylene glycol-epoetin beta [Mircera]"]}],"interventions":[{"name":"methoxy polyethylene glycol-epoetin beta [Mircera]","otherNames":["C.E.R.A."]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients \\>=18 years of age;\n* chronic renal anemia;\n* regular long-term hemodialysis or peritoneal dialysis, with same mode of dialysis for \\>=3 months;\n* continuous iv maintenance epoetin alfa therapy with same dosing interval during previous 2 months.\n\nExclusion Criteria:\n\n* transfusion of red blood cells during previous 2 months;\n* poorly controlled hypertension;\n* significant acute or chronic bleeding;\n* active malignant disease (except non-melanoma skin cancer).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Maintaining Mean Hemoglobin Concentration Within +/- 1 g/dL of Their Reference Hb and Between 10.5 and 12.5 g/dL During Efficacy Evaluation Period","description":"The percentage of participants who maintained their mean Hb concentration within +/- 1 g/dL of their reference Hb and between 10.5 and 12.5 g/dL during the Efficacy Evaluation Period (EEP) is reported. The EEP was from Week 17 to Week 24. The reference Hb was calculated from the mean of Hb concentrations based upon the Hb assessments at Weeks -4, -3, -2, -1, and 0.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Hemoglobin Concentration Between Reference (Stability Verification Period) and the Efficacy Evaluation Period","description":"Mean change in Hb concentration between reference SVP and the EEP is reported. The SVP was at Weeks -3, -2, -1, and EEP was from Week 17 to Week 24. Participants received epoetin alfa or beta during SVP.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Maintaining Hemoglobin Concentration Within the Range of 10.5-12.5 g/dL Throughout the EEP","description":"Percentage of participants maintaining Hb concentration within the range of 10.5-12.5 g/dL throughout the EEP is reported. The EEP was from Week 17 to Week 24.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Time Spent By Participants With Hemoglobin Range of 10.5-12.5 g/dL During the EEP","description":"Mean time spent by participants in Hb range of 10.5-12.5 g/dL during the EEP is reported. The EEP was from Week 17 to Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":"19.85"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Adverse Events or Serious Adverse Events","description":"An adverse event (AE) is untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAEs) is with any of the following outcomes: Death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, and congenital anomaly.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Any Dose Adjustment During DTP and EEP","description":"Percentage of participants requiring any dose adjustment during DTP (Week 1 to Week 16) and EEP (Week 17 to Week 24) is reported. The dose adjustments (increase or decrease) were required: if a single Hb concentration was either \\> or = 13 g/dL or \\< or = 9 g/dL; if the difference of 2 consecutive Hb concentrations was \\> or =2 g/dL; if the values of scheduled Hb assessments on the day of administration of C.E.R.A. and on the previous study visit were both out of range of 10.5 to 11.5 g/dL, the difference between the reference value (mean of Hb concentrations based on the Hb assessments at Weeks -4, -3, -2, -1, and 0) and the most recent value was \\>1 g/dL; if the values of the scheduled Hb assessments on the day of administration of C.E.R.A. and on the previous study visit were both out of the range 10 to 12 g/dL. Dose adjustment could be made at any time at the discretion of the clinician if clinically warranted.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidences of Red Blood Cell Transfusions During the C.E.R.A. Treatment Phase","description":"Red Blood Cells (RBCs) transfusions were given during the treatment period in case of medical need. Blood transfusions occurred during the DTP, EEP, and during the long term safety period (LTSP) were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Hemoglobin Levels Over Time","description":"The Hb levels were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Mean Hematocrit Levels Over Time","description":"The hematocrit (HCT) levels were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Mean Albumin Levels Over Time","description":"The albumin levels were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":"8.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":"6.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":"6.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":"6.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.9","spread":"6.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":"6.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.9","spread":"7.26"}]}]}]},{"type":"SECONDARY","title":"Mean White Blood Cells and Thrombocytes Over Time","description":"The white blood cells (WBCs) and thrombocyte levels were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"1.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"1.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"1.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"1.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"1.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213.9","spread":"68.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207.5","spread":"65.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202.5","spread":"58.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"200.5","spread":"55.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"208.6","spread":"69.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206.1","spread":"68.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204.7","spread":"68.95"}]}]}]},{"type":"SECONDARY","title":"Mean Phosphate and Potassium Levels Over Time","description":"The phosphate and potassium levels were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Mean Creatinine, Iron, and Total Iron Binding Capacity Levels Over Time","description":"The mean creatinine, iron, and total iron binding capacity (TIBC) levels over time were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"775.7","spread":"477.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"692.5","spread":"502.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"676.1","spread":"490.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"683.7","spread":"472.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"670.2","spread":"477.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"674.8","spread":"488.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"699.6","spread":"444.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":"8.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"7.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"6.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"5.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":"5.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"5.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"5.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.5","spread":"11.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":"10.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":"12.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":"11.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":"11.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":"10.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":"10.37"}]}]}]},{"type":"SECONDARY","title":"Mean C-Reactive Protein Levels Over Time","description":"The mean C-Reactive Protein (CRP) Levels over time were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"8.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"8.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"11.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"13.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"7.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"7.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"8.76"}]}]}]},{"type":"SECONDARY","title":"Mean Ferritin Levels Over Time","description":"The mean ferritin levels over time were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"547.6","spread":"896.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"522.2","spread":"772.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"517.6","spread":"639.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"508.6","spread":"577.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"522.6","spread":"874.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"562.8","spread":"984.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"505.6","spread":"770.48"}]}]}]},{"type":"SECONDARY","title":"Mean Transferrin Saturation Levels Over Time","description":"The mean transferrin saturation (TSAT) levels over time were recorded for each participant at enrolment and at different time points during the study up to Week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":"20.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":"16.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":"18.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":"18.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":"14.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":"15.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":"17.56"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Pulse Rate Over Time","description":"Mean change in pulse rate was defined as the difference between mean pulse rate at Baseline and following visits (Weeks 8, 16, 24, 32, 40, and 48).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"6.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"6.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"6.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"6.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"8.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"8.69"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Blood Pressure Over Time","description":"Mean change in blood pressure (systolic blood pressure \\[SBP\\] and diastolic blood pressure \\[DBP\\]) before and after dialysis was defined as the difference between mean blood pressure at Baseline and following visits (Weeks 8, 16, 24, 32, 40, and 48).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"14.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"13.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"13.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"14.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"13.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"13.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"12.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"12.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"13.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"14.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"11.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"13.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"11.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":"11.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":"11.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"9.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.35","spread":"10.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"10.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"9.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"10.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"9.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.07","spread":"8.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"8.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"10.11"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Weight Over Time","description":"Mean change in weight was defined as the difference between mean weight at Baseline and following visits (Week 16 and Week 48).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"3.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"3.21"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":194},"commonTop":["Bronchitis","Gastrointestinal haemorrhage","Hypotension"]}}}